LOGIN | Register
Cooperation
新氧科技 (SY.US) 2025年第二季度业绩电话
文章语言:
EN
Share
Minutes
原文
会议摘要
SoYoung's aesthetics center business achieved significant growth, becoming the largest revenue contributor. Despite a decrease in medical service providers, total revenue was RMB 378.7 million, with aesthetic treatment services soaring to RMB 144.4 million. The company plans to open around 10 new centers, targeting fourth- and second-tier cities, emphasizing standardized service delivery, health care quality, compliance, and user experience. Management highlighted competitive advantages in low-cost customer acquisition, a diversified supply chain, and operational efficiency, aiming for sustainable, high-quality, long-term growth.
会议速览
Financial Report for the Second Quarter of 2025 and Future Prospects
At this meeting, the company announced the financial performance for the second quarter of 2025 and conducted a detailed analysis. The meeting began with a welcome speech by the host who reminded participants of the importance of the safe harbor statement. The floor was then handed over to the CEO, who led the team in a thorough analysis of the financial data, including explanations and adjustments for non-GAAP metrics. Finally, the meeting moved on to a Q&A session, inviting investors and analysts to ask questions in order to gain a more comprehensive understanding of the company's financial situation and future strategies.
Brand Asset Center business grows strong, Aesthetic Center business becomes the largest source of income.
During the discussion, it was mentioned that the Brand Asset Center business maintained a strong momentum, achieving growth in revenue and quality, and its business model and strategic direction gained high market recognition. In particular, in the field of Aesthetics Central business, revenue exceeded expectations, becoming the largest revenue contributing sector for the first time, marking a key turning point in the company's years of strategic transformation, ushering in a new growth stage.
Soyang Company's Second Quarter Financial Report and Future Outlook: Network Expansion and Operational Efficiency Improvement.
The conversation mainly revolves around Soyang Company's financial performance in the second quarter, including the situation of RMB losses, as well as the company's strategic planning for the future, such as optimizing service processes, enhancing customer experience, and strengthening brand influence to achieve long-term sustainable high-quality growth. At the same time, the rapid expansion of the company's network and continued investment, resulting in currently owning 33 centers, are also mentioned.
Strong Growth in Beauty Services Performance and Operational Efficiency Improvement in the Second Quarter
The report shows a significant increase in revenue from beauty services in the second quarter, as well as an increase in the number of beauty centers, the number of treatments for active users, and an improvement in operational efficiency. The beauty centers achieved positive cash flow and monthly profits in June, with high customer satisfaction and customer acquisition costs maintained at a low level. Through standardized service delivery, enhanced medical quality and user experience, and digital management, the entire process from appointment to treatment has been standardized, improving user transparency and traceability.
New therapy collaborates with brands: Expand medical assets, enhance brand influence.
By launching new therapies such as Miracle Pl, Mermaid Skin Bolster, and BBC Hero, we have successfully expanded our medical asset portfolio, increased ARPU, and strengthened our competitiveness. By partnering with international IP Belly Group, we have attracted a large number of young users through immersive experiential activities, significantly increasing brand awareness and offline interaction. At the same time, we have collaborated with the Zoo team to enhance our brand philosophy with emotional stories, effectively increasing female users' perception of our brand's professionalism and market leadership.
The plan is to expand the medical beauty center in the third quarter of 2023, with a nationwide coverage of up to 50 locations.
The plan is to add approximately 50 E family medical beauty centers nationwide in the third quarter of 2023, including fourth-tier cities and less popular second-tier cities, in order to enhance market leadership. At the same time, standardize operations and innovate products will be strengthened to improve service accessibility and solidify the leading position in the Chinese medical beauty industry.
Expansion of the medical beauty supply chain and market coverage strategy in 2025.
The dialogue discussed the expansion plan of the medical beauty supply chain, including product certification, cost efficiency improvement, and industry-wide chain collaboration. The goal is to increase the density of clinics in first-tier cities by 2025, cover second and third-tier cities, improve user experience and operational efficiency, consolidate core competitiveness, and create long-term value for shareholders. Meanwhile, it emphasizes digital operation support to ensure the healthy development of the platform, achieve user value innovation, and explore broader growth opportunities.
Company Financial Report and Future Outlook: Decreased Revenue and Expansion of Brand Beauty Centers
In the second quarter, the company's total revenue was 3.787 million RMB, a decrease compared to the same period last year, primarily due to a decrease in the number of medical providers subscribing to information services. Revenue from beauty treatment services saw significant growth, reaching 1.444 million RMB, exceeding expectations, thanks to the expansion of the business of branded beauty centers. Looking ahead to the third quarter, it is expected that revenue from beauty treatment services will increase significantly. The company is accelerating the construction of branded beauty center networks, aiming to reach the predetermined number by the end of the year. At the same time, the company is optimizing operational efficiency to consolidate its leading position in the industry and create long-term value.
Expansion plan and long-term strategic objectives for the years 2023-2024.
The conversation detailed the expansion plans for 2023 and 2024, with the goal of adding 10 new centers within the year and reaching a total of 10 centers in Beijing by the end of 2025. The long-term goal is to expand the network to more cities by improving organizational capabilities, with plans to achieve a target of 100 centers within 3-4 years. While franchise models are not currently a priority, their feasibility will be assessed through pilot programs in the future to support wider expansion.
Analysis of potential and competitive advantages in the Chinese medical beauty market.
The conversation discussed the growth potential of the Chinese medical beauty market, pointing out that compared to foreign markets, the penetration rate of the Chinese market is lower, and there is a huge market space in the future. It is estimated that by 2030, it will reach about 340 billion yuan. Industry leaders, with sustainable low-cost customer acquisition, diversified supply chain support, and large-scale physical network operation capabilities, are expected to occupy about 20% of the market share, realizing nearly 260 billion yuan in market opportunities.
Customer acquisition cost and outlook on cost structure optimization.
Discussed the future outlook of customer acquisition costs, emphasizing the importance of private domain traffic and existing customer referrals. At the same time, mentioned increasing the proportion of self-controlled products and optimizing cost structure to improve efficiency, including launching new medical aesthetic equipment and upstream injection products, as well as strategies to reduce consumable costs.
Innovations in recruitment and management of talents in the medical beauty industry.
Discussed the current situation and future challenges of doctor recruitment in the medical beauty industry, emphasizing the importance of a solid talent base and standardized technological requirements in the industry. Also highlighted the support for the growth of doctors through professional training and the construction of regional centers. At the same time, introduced the transformation of the role of center managers and the use of digital management platforms to improve operational efficiency and management levels, looking forward to further optimizing the direction of digital management in the future.
The uniqueness of Soyo's product strategy and planning, as well as its future development direction.
The core of Soyo's product strategy was discussed, which focuses on anti-aging treatments to ensure product line consistency, emphasizes overall cost-effectiveness, and avoids relying on loss-making products to attract customers. It was proposed to optimize the product portfolio and dynamically adjust core therapeutic projects to meet changing market demands and maintain a leading position in the industry. In the future, close attention will be paid to market trends, timely launch of potential new products, and strengthening brand influence.
Discussion on the Future Development Plan of the Group Aesthetic Center and POW Business.
In the conversation, in addition to discussing the business of the Group's Aesthetics Center, the future development plan of the POW business was also discussed, including the expansion plan in Shanghai and surrounding areas. It was mentioned that although there was some fluctuation in revenue from the POW business this quarter, it still remains a key source of profit for the group, and high profit margins will be maintained through strict cost control.
Classification of platform merchants and strategies to improve traffic conversion efficiency.
With the continuous expansion of asset expansion network, the plan is to establish a more accurate merchant classification rating mechanism through user behavior and service data in order to achieve efficient conversion of high-quality traffic, including acquiring new customers and promoting standardized light medical beauty services, while meeting the needs of non-surgical and minimally invasive surgery. Through platform optimization, precise matching between merchants and users is promoted to create incremental value.
要点回答
Q:What are the highlights of SoYang's second quarter 2025 earnings?
A:SoYang's second quarter 2025 earnings saw robust momentum in branded asset center business with growth in both revenue and quality. The company generated total revenue of RMB circulation, with the aesthetics central business reaching RMB circulation million, surpassing the upper end of guidance and becoming the largest revenue contributor segment for the first time. The business model and strategic direction have received strong market recognition, and the company experienced a critical inflection point in its multi-year strategic transition.
Q:What were the financial results for SoYang's branded asset center business in the second quarter?
A:In the second quarter, SoYang's branded asset center business recorded a net loss attributable to SoYang of RMB script million and a non-GAAP net loss of RMB 30.5 million. The company attributes this to ongoing investments and the rapid network expansion.
Q:What operational achievements did SoYang accomplish in the second quarter?
A:During the second quarter, SoYang's operational achievements included strong growth in treatment services revenue with a quarter-over-quarter and year-over-year increase to RMB circulation million. The company also saw an improvement in center performance, with 29 aesthetic centers operated by the end of June, and 13 of them being open for more than a year. Furthermore, SoYang achieved cash flow positivity in June and had 16 profitable centers by the end of the quarter. The company maintained a high repeat purchase rate and customer satisfaction score, and saw a significant increase in the number of active users and excess treatments performed. SoYang also led in customer acquisition efficiency and kept average customer acquisition costs within the hundreds RMB range.
Q:How is SoYang committed to ensuring healthcare quality and user experience?
A:SoYang remains committed to standardized service delivery and focuses on healthcare quality, compliance, and user experience. The company has implemented a physician selection and training system for all over 100 full-time medical doctors, with most having completed internships or standardized training in public hospitals and nearly all being specialists. SoYang is also advancing toward full process standardization using AI-driven solutions from self-service check-in to treatment, ensuring a transparent and traceable medical experience for every user.
Q:What new treatments were launched by SoYang in the second quarter?
A:SoYang launched several highly acclaimed treatments in the second quarter, including Miracle Pl, Mermaid Skin Bolster, and BBC Hero, which expanded their medical assets portfolio, increased ARPU, and reinforced their competitive edge.
Q:What branding and marketing strategies has SoYang implemented?
A:SoYang partnered with the international IP group Belley to stage events around their miracle PLA series in Beijing and Shenzhen CBDs during the quarter. These events, combined with emotional storytelling through self-media influencers, strongly resonated with the core female user base and effectively reinforced SoYang's professional reputation and brand positioning among savvy beauty-conscious women.
Q:What are SoYang's plans for the third quarter and full year in terms of aesthetic centers?
A:For the third quarter, SoYang plans to open around 15 aesthetic centers, expanding into both fourth-tier cities and selected secondary cities. Looking ahead to the full year, the company expects the total number of aesthetic centers to reach 50, further enhancing the accessibility of SoYang clinics across China and solidifying their leading positions in the country's medical aesthetic industry.
Q:How is SoYang's upstream business performing?
A:SoYang's upstream business is continuing to build out the medical aesthetic supply chain, driving nationwide penetration of self-developed and exclusively distributed products. By the end of the quarter, the number of institutions receiving supply chain solutions for injectables exceeded 1600, with shipments of elastic reaching around 39,100 units. As the company's upstream products gain additional certifications and scale, it is expected to enhance its advantage and improve cost efficiency, solidifying its market position.
Q:What was the performance of the top business and the verified medical aesthetic services during the quarter?
A:The top business remained stable during the quarter with verified medical aesthetic services reaching roughly RMB 300 million. Per capita in center GTV grew by 6% year over year.
Q:How is the company planning to increase market coverage and operational efficiency?
A:The company aims to increase market coverage and operational efficiency by localized bright fielding and remains committed to refining the user experience and center operational efficiency.
Q:What are the financial results for the quarter mentioned in the speech?
A:Total revenue during the quarter was RMB 378.7 million, down year over year due to a decrease in the number of medical service providers using information services. Aesthetic treatment service revenues reached RMB 144.4 million, up significantly year over year. Information and reservation services revenues were down, primarily due to fewer medical service providers using platform services. Sales of medical products and maintenance services revenues were down, mainly because of decreased medical product order volume. Other services revenues also declined due to a decrease in soyang.
Q:How did the cost of revenues change, and what was the reason for the change?
A:The cost of revenues was RMB 16.2 million, up year over year, primarily due to business expansion at branded aesthetic centers. The cost of aesthetic treatment services increased to RMB 109.4 million, up 405.5% year over year, primarily for the same reason. The cost of information and reservation services decreased to RMB 16.7 million, down 40% year over year, in line with the decrease in revenue from these services.
Q:What is the company's outlook for the third quarter?
A:The company expects aesthetic treatment service revenues in the third quarter to be between RMB 400 million and RMB 500 million, representing a 230.5% to 274.6% increase from the same period last year. This outlook reflects ongoing network expansion towards the year-end target of 150 centers with ample cash reserves and a demonstrated track record of execution.
Q:What is the plan for the franchising model?
A:The company's immediate focus is not on franchising due to the manageable CapEx and short payback period of operating centers, supported by ample cash reserves for rapid expansion. However, the franchise model will play an important role in future expansion, with plans to pilot 20 to 25 franchise centers in Q4 based on the operational performance of pilot centers.
Q:What is management's view on the growth potential of the Chinese aesthetic market and the company's adaptability to competition?
A:The text does not provide a direct answer to this question. However, it implies that management views the growth potential of the Chinese aesthetic market positively and is confident in the company's ability to adapt to the competitive challenges within the market.
Q:What are the growth prospects and market share predictions for China's medical aesthetics industry?
A:China's medical aesthetics market, currently with a lower penetration rate compared to mature overseas markets like South Korea, is forecasted to substantially grow. The sector represents a distinct model with faster growth and easier customer mind share capture. It is expected to reach around RMB 340 billion by 2030, and a leading company in this industry could achieve roughly 20% market share, translating to nearly RMB 26 billion in market opportunities.
Q:What are the essential core capabilities for success in the medical aesthetic chain business?
A:To succeed in the medical aesthetic chain business, essential core capabilities include sustainable low-cost customer acquisition, diversified upstream supply chain support, and organizational competence in operating a large-scale physical network.
Q:What is the current customer acquisition cost and strategy for future cost reduction?
A:Currently, Soo's average customer acquisition cost is only a few hundreds RMB, with most new customers coming from low-cost private domain traffic and referrals from existing customers. The company plans to maintain low costs by leveraging private domain traffic and strong conversion rates from referrals without aggressive sales or pre-paid membership card requirements. To further optimize costs, Soo is increasing the proportion of self-controlled offerings used in their aesthetic centers, developing medical lasers, holding exclusive distribution rights for treatments, and collaborating with upstream manufacturers to launch new products. These strategies are expected to reduce consumable costs and improve the company's procurement power.
Q:What is Soo's strategy for recruiting and training medical staff?
A:Soo focuses on recruiting medical staff for life medical aesthetic services, where technical requirements can be standardized. New recruits can quickly gain practical experience and be brought up to speed. The company operates a high-quality team with all full-time doctors having completed internships or standardized training at public hospitals and nearly 90% specializing in dermatology. A diagnosis and treatment system matches treatments to doctors based on their level, and regional training centers provide professional growth support.
Q:How does Soo manage its centers and what are the future plans for the centers' operations?
A:Soo's online appointment booking and onsite service verification model reduces reliance on center managers, who mainly handle on-site management. The company assesses managers on operational metrics like safety, customer experience, and consultation efficiency. Digital operations handle doctor and nurse recruitment, product management, pricing, and marketing. A digital dashboard allows headquarters to monitor center operations in real-time. Going forward, the company aims to enhance digital management maturity to reduce costs.
Q:What is Soo's product strategy and how does it differentiate from competitors?
A:Soo's product strategy emphasizes overall cost-effectiveness and focuses on anti-aging treatments developed around a core theme of consistency across the portfolio. Unlike some institutions that rely on low-priced single products to attract customers, Soo ensures each treatment provides a healthy growth margin and does not use loss-making products for customer acquisition.
Q:What future plans does Soo have for its P&O business?
A:Soo plans to maintain strict cost controls to preserve the profitability of its parts business, which has high growth margins and is a key component of the group's profitability. The company intends to leverage user behavior and a merchant classification rating mechanism on its platform to enhance traffic monetization efficiency and create incremental growth for the pop business. As the asset expansion network grows, Soo expects to generate high-quality traffic through referral programs and public domain traffic, converting it into demands for procedures at Soo clinics.
play
English
English
进入会议
1.0
0.5
0.75
1.0
1.5
2.0